AstraZeneca’s Diabetes Drug Onglyza May Raise Death Risk, FDA Says

AstraZeneca Plc’s type 2 diabetes drug Onglyza showed an increased risk of death in an analysis by U.S. regulators of a clinical trial on the heart effects of the treatment.

Please review with your doctor if this risk applies to you

Food and Drug Administration staff said their analysis of deaths in the trial suggested patients using Onglyza experienced “significant or near-significant” increases in death from all causes, not just heart problems.

The FDA staff didn’t find an increase in deaths related to Nesina, according to the report. Merck & Co. sells a related drug, Januvia, that is also being studied though hasn’t yet released the results of its heart risk trial.

http://www.bloomberg.com/news/articles/2015-04-10/astrazeneca-type-2-diabetes-drug-may-raise-death-risk-fda-says